Vinblastine (NSC-49842) plus vincristine (NSC-67574) given in intensive 3-day courses as therapy for lymphomas, sarcomas, and other neoplasms.
D000505:Alopecia / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000139:chemically induced; D012509:Sarcoma / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D014750:Vincristine; D014747:Vinblastine